Drug Profile
ZYG 19
Alternative Names: ZYG19Latest Information Update: 07 Sep 2016
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 08 Oct 2015 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in India (PO) (Zydus pipeline, October 2015)
- 07 Apr 2014 Phase-I development is ongoing in India
- 30 Dec 2011 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in India (PO)